The tumor-growth inhibitory activity of flavanone and 2′-OH flavanone in vitro and in vivo through induction of cell cycle arrest and suppression of cyclins and CDKs

Journal of Biomedical Science

Volumn 14, Issue 1, 2007, Pages 107-119

  Hsiao, Yung Chin ^a   Hsieh, Yih Shou ^a   Kuo, Wu Hsien ^b,c   Chiou, Hui Ling ^a   Yang, Shun Fa ^a,c   Chiang, Whei Ling ^a   Chu, Shu Chen ^c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

A549 human lung cancer cells; Cyclin CDK complex; Flavanone compounds

Indexed keywords

2' HYDROXYFLAVANONE; 4' HYDROXYFLAVANONE; 6' HYDROXYFLAVANONE; AURANTIIN; CELL CYCLE PROTEIN; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLINE; DOXORUBICIN; FLAVANONE; NARINGENIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLINS; DOXORUBICIN; DRUG SYNERGISM; FLAVANONES; G2 PHASE; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM PROTEINS;

EID: 33847156848     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9117-3     Document Type: Article

References (43)

1. Grana X. and Reddy E.P., Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219, 1995.
2. Swanton C., Cell-cycle targeted therapies. Lancet Oncol. 5: 27-36, 2004.
3. MacLachlan T.K., Sang N. and Giordano A., Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr. 5: 127-156, 1995.
4. Vermeulen K., Van Bockstaele D.R. and Berneman Z.N., The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36: 131-149, 2003.
5. Hall M. and Peters G., Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68: 67-108, 1996.
6. Shyur L.F., Chen C.H., Lo C.P., Wang S.Y., Kang P.L., Sun S.J., Chang C.A., Tzeng C.M. and Yang N.S., Induction of apoptosis in MCF-7 human breast cancer cells by phytochemicals from Anoectochilus formosanus. J. Biomed. Sci. 11: 928-939, 2004.
7. Wang X., Jia W. and Zhao A., Anti-influenza agents from plants and traditional Chinese medicine. Phytother. Res. 20: 335-341, 2006.
8. Huh S.W., Bae S.M., Kim Y.W., Lee J.M., Namkoong S.E., Lee I.P., Kim S.H., Kim C.K. and Ahn W.S., Anticancer effects of (-)-epigallocatechin-3- gallate on ovarian carcinoma cell lines. Gynecol. Oncol. 94: 760-768, 2004.
9. Lee H.Z., Leung H.W., Lai M.Y. and Wu C.H., Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res. 25: 959-964, 2005.
10. Lee K.H., Anticancer drug design based on plant-derived natural products. J. Biomed Sci. 6: 236-250, 1999.
11. Weng M.S., Ho Y.S. and Lin J.K., Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21Waf1/Cip1 expression: involvement of p38 mitogen-activated protein kinase. Biochem. Pharmacol. 69: 1815-1827, 2005.
12. Manthey J.A., Grohmann K. and Guthrie N., Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr. Med. Chem. 8: 135-153, 2001.
13. Moulari B., Pellequer Y., Lboutounne H., Girard C., Chaumont J.P., Millet J. and Muyard F., Isolation and in vitro antibacterial activity of astilbin, the bioactive flavanone from the leaves of Harungana madagascariensis Lam. ex Poir. (Hypericaceae). J. Ethnopharmacol. 106: 272-278, 2006.
14. Yao H., Liao Z.X., Wu Q., Lei G.Q., Liu Z.J., Chen D.F., Chen J.K. and Zhou T.S., Antioxidative flavanone glycosides from the branches and leaves of Viscum coloratum. Chem. Pharm. Bull. (Tokyo) 54: 133-135, 2006.
15. Manthey J.A. and Guthrie N., Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 50: 5837-5843, 2002.
16. Kohno H., Taima M., Sumida T., Azuma Y., Ogawa H. and Tanaka T., Inhibitory effect of mandarin juice rich in beta-cryptoxanthin and hesperidin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary tumorigenesis in mice. Cancer Lett. 174: 141-150, 2001.
17. Tanaka T., Makita H., Kawabata K., Mori H., Kakumoto M., Satoh K., Hara A., Sumida T., Fukutani K. and Ogawa H., Modulation of N-methyl-N- amylnitrosamine-induced rat oesophageal tumourigenesis by dietary feeding of diosmin and hesperidin, both alone and in combination. Carcinogenesis 18: 761-769, 1997.
18. Tanaka T., Makita H., Ohnishi M., Mori H., Satoh K., Hara A., Sumida T., Fukutani K. and Ogawa H., Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res. 57: 246-252, 1997.
19. Yang M., Tanaka T., Hirose Y., Deguchi T., Mori H. and Kawada Y., Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int. J. Cancer 73: 719-724, 1997.
20. Ko C.H., Shen S.C., Lin H.Y., Hou W.C., Lee W.R., Yang L.L. and Chen Y.C., Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process. J. Cell Physiol. 193: 93-102, 2002.
21. Okuda T., Yoshida T. and Hatano T., Pharmacologically active tannins isolated from medicinal plants. Basic Life Sci. 59: 539-569, 1992.
22. Bost F., McKay R., Bost M., Potapova O., Dean N.M. and Mercola D., The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol. Cell. Biol. 19: 1938-1949, 1999.
23. Bai L., Zhu R., Chen Z., Gao L., Zhang X., Wang X. and Bai C., Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. Biochem. Pharmacol. 71: 1265-1271, 2006.
24. Chen P.N., Chu S.C., Chiou H.L., Chiang C.L., Yang S.F. and Hsieh Y.S., Cyanidin 3-glucoside and peonidin 3-glucoside inhibit tumor cell growth and induce apoptosis in vitro and suppress tumor growth in vivo. Nutr. Cancer 53: 232-243, 2005.
25. Chen P.N., Hsieh Y.S., Chiou H.L. and Chu S.C., Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact. 156: 141-150, 2005.
26. Zi , Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res. 65: 3479-3486, 2005.
27. Sigounas G., Sallah S. and Sigounas V.Y., Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett. 214: 171-179, 2004.
28. Cos P., De Bruyne T., Hermans N., Apers S., Berghe D.V. and Vlietinck A.J., Proanthocyanidins in health care: current and new trends. Curr. Med. Chem. 11: 1345-1359, 2004.
29. Di Carlo G., Mascolo N., Izzo A.A. and Capasso F., Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci. 65: 337-353, 1999.
30. Areias F.M., Rego A.C., Oliveira C.R. and Seabra R.M., Antioxidant effect of flavonoids after ascorbate/Fe(2+)-induced oxidative stress in cultured retinal cells. Biochem. Pharmacol. 62: 111-118, 2001.
31. Hendriks J.J., de Vries H.E., van der Pol S.M., van den Berg T.K., van Tol E.A. and Dijkstra C.D., Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. Biochem. Pharmacol. 65: 877-885, 2003.
32. Shen S.C., Ko C.H., Tseng S.W., Tsai S.H. and Chen Y.C., Structurally related antitumor effects of flavanones in vitro and in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production. Toxicol. Appl. Pharmacol. 197: 84-95, 2004.
33. Singh R.P., Dhanalakshmi S. and Agarwal R., Phytochemicals as cell cycle modulators - a less toxic approach in halting human cancers. Cell Cycle 1: 156-161, 2002.
34. Connell-Crowley L., Harper J.W. and Goodrich D.W., Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell. 8: 287-301, 1997.
35. Zarkowska T. and Mittnacht S., Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 272: 12738-12746, 1997.
36. Elledge S.J. and Harper J.W., Cdk inhibitors: on the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6: 847-852, 1994.
37. Carlson B., Lahusen T., Singh S., Loaiza-Perez A., Worland P.J., Pestell R., Albanese C., Sausville E.A. and Senderowicz A.M., Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 59: 4634-4641, 1999.
38. Buccheri G., Ferrigno D. and Rosso A., A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer 72: 1564-1572, 1993.
39. van Acker F.A., Boven E., Kramer K., Haenen G.R., Bast A. and van der Vijgh W.J., Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity. Clin. Cancer Res. 7: 1378-1384, 2001.
40. Von Hoff D.D., Layard M.W., Basa P., Davis H.L. Jr., Von Hoff A.L., Rozencweig M. and Muggia F.M., Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91: 710-717, 1979.
41. Tyagi A.K., Agarwal C., Chan D.C. and Agarwal R., Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol. Rep. 11: 493-499, 2004.
42. Zhang X.Y., Bai D.C., Wu Y.J., Li W.G. and Liu N.F., Proanthocyanidin from grape seeds enhances anti-tumor effect of doxorubicin both in vitro and in vivo. Pharmazie 60: 533-538, 2005.
43. Manach C., Morand C., Gil-Izquierdo A., Bouteloup-Demange C. and Remesy C., Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur. J. Clin. Nutr. 57: 235-242, 2003.